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Abstract:
We aim to evaluate the potential benefit and risk of addition of vorapaxar to standard medical therapy in patients who underwent coronary revascularization with either percutaneous coronary revascularization (PCI) or coronary artery bypass graft surgery (CABG).We searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and the clinical trial registry maintained at clinicaltrials.gov for randomized control trials evaluating the safety and efficacy of vorapaxar in patients who underwent coronary revascularization procedures with either PCI or CABG. Event rates were compared using a Forest plot of relative risk using a random effects model. The five studies (N=24,025) that met all criteria were included in the final analysis. After coronary revascularization procedures, addition of vorapaxar to standard medical therapy was 
INTRODUCTION:
Recently, the Food and Drug Administration (FDA) has approved vorapaxar for long-term secondary prevention of atherothrombotic events in stable patients with a prior myocardial infaction (MI) or peripheral arterial disease (PAD), and without history of stroke or transient ischemic attack [1] . However, it remains largely unclear if addition of PAR1 antagonists would have an incremental benefit when added to current standard therapy in patients who underwent coronary revascularization procedures (PCI or CABG), which is of particular interest, as this patient population is at increased risk of rethrombosis, especially stent thrombosis (ST) and graft occlusion, mediated by persistent platelet activating mechanisms [2] [3] [4] . Hence, in the current meta-analysis, we evaluated the potential benefit and risk of addition of vorapaxar to standard in patients who underwent coronary revascularization with either PCI or CABG.
METHODS:
We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for reporting systematic reviews and meta-analyses of RCTs for the protocol of our meta-analysis [5] . We searched PubMed, EMBASE, the Cochrane Two reviewers (AS, SG) independently screened the titles and abstracts for relevance. The manuscripts of selected titles/abstracts were reviewed for inclusion or exclusion using the above mentioned selection criteria. Two reviewers (AS, AG) independently determined the articles to be included and excluded, and data from the relevant articles were extracted using pre-defined extraction forms. Any disagreements in data extraction were discussed until consensus was reached. Key study and patient characteristics were extracted, including the following outcomes, reported at the longest (RR) and 95% confidence interval, associated with vorapaxar versus placebo for above end points. Forest plot was used to observe the overall effect of studies. Heterogeneity between studies was assessed using Cochrane's Q test and I 2 statistic, which denotes the percentage of total variation across studies that is a result of heterogeneity rather than chance. Heterogeneity was considered significant if the p value was less than 0.05.
Publication bias was assessed by Begg's test and Egger's regression test.
RESULTS:
Five studies (N=24,025) are selected for final analysis ( 
DISCUSSION:
Our results demonstrated that the addition of vorapaxar to standard medical therapy after coronary revascularization procedures a) does not lead to statistically significant reduction in CV mortality, TVR and ST; b) there was a significant reduction in the rate of subsequent MI and ischemic stroke in patients who received vorapaxar; c) the use of vorapaxar was associated with significant increases in the rates of hemorrhagic stroke, and clinically significant TIMI major and minor bleeding.
Consistent with the overall cohort in TRACER trial, the sub-group of patients who underwent coronary stenting for index non-ST segment MI (NSTEMI) experienced a numerically lower, but non-significant, decrease in combined end-point of CV mortality, MI and stroke [7] . Further, in NSTEMI patients undergoing CABG, use of
vorapaxar was associated with a significant reduction in ischemic events and without any significant increase in major CABG-related bleeding [8] . On the contrary, stable patients in TRA 2P-TIMI study who received vorapaxar post-stenting after a median of 3 months showed significant long-term benefit for the same composite end-point [10] . Similar to the overall results, this was primarily driven by a decrease in incidence of recurrent MI [10] . Additionally, there was no significant benefit in CV mortality in either study, which is also in concurrence with our pooled analysis [7, 10] . It is worth mentioning that TRACER and TRA 2P-TIMI trials differed in patient selection in terms of acute coronary syndrome versus stable coronary artery disease and hence use of more aggressive antithrombotic therapy, including direct thrombin and glycoprotein IIb/IIIa inhibitors in the acute setting that might offset small differences in benefit with additional therapy.
Interestingly, in the subgroup of patients receiving bare metal stent (BMS) in TRACER trial, statistical significance was reached for the combined end-point (CV mortality, MI, stroke), as well as individual end-point of MI and stroke, leading to postulation of treatment effect of shorter thienopyridine therapy (133 vs 221 days) in BMS, as compared to drug-eluding stents group [7] .
Consistent with the results from main phase III trials, vorapaxar led to significantly increased risk of major bleeding events, including ICH [11, 12] . In the phase II studies involving patients undergoing PCI, vorapaxar demonstrated a trend towards lesser thrombotic events compared to placebo without exposing to an increase in bleeding risk [6, 9] . It was postulated that while inhibiting thrombin-mediated platelet activation, PAR1 antagonism might not interfere with the hemostatic pathway and, thus, not predispose to a higher bleeding risk [6, 9] . However, in phase 3 trials, the magnitude M A N U S C R I P T 7 7 of the increased bleeding rates was much higher than expected on the basis of the preclinical and phases 2 trials, which suggested that vorapaxar did not significantly increase the risk of bleeding, over and above that of standard DAPT with aspirin and clopidogrel [6] [7] [8] [9] [10] . In fact, the TRACER trial was terminated early because of the observed significant increase in major bleeding, [12] and in the TRA-2P TIMI 50 trial, the data and safety monitoring board recommended the discontinuation of vorapaxar in patients with a history of stroke on the basis of an excess of ICH in such patients [11] .
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This disparity could be explained by the fixed dosing schedule and the longer duration of the anticoagulation given to patients in these trials. Although the increased rate of ICH related to use of vorapaxar can be attributed to intensive antithrombotic therapy (triple antiplatelet therapy), the possibility of a specific role of PAR-1 inhibition and intracranial vascular hemostasis can not be completely ruled out and still needs to be investigated.
Our study has several limitations. First, improvement in clinical outcomes with vorapaxar is primarily driven by a reduction in MI. However, MI itself is a heterogeneous group of events with different underlying mechanisms, and it is possible that vorapaxar might not affect all of these mechanism to similar extent. Furthermore, the varying extent and location of MIs could have different clinical implications. In the current analysis, we
were not able to evaluate effect of the addition of vorapaxar on various types and extent of MI due to non-availability of data. Second, TRACER trial was stopped prematurely and the sub-group of stroke in TRA 2P-TIMI was excluded from the trial due to a significant increase in fatal bleeding, including ICH [11, 12] . Thus, one of the potential caveats in interpretation of bleeding risk in our study is the inclusion of FDA-contraindicated populations (prior stroke or TIA) in the sub-group studies, which were included M A N U S C R I P T Additional records identified through other sources (n=0)

